![](/img/cover-not-exists.png)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
Chi, K. N., Yu, E. Y., Jacobs, C., Bazov, J., Kollmannsberger, C., Higano, C. S., Mukherjee, S. D., Gleave, M. E., Stewart, P. S., Hotte, S. J.Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw068
Date:
February, 2016
File:
PDF, 161 KB
english, 2016